Formycon AG Appoints Top US Pharmaceuticals Manager Bernhard Hampl to the Advisory Board
Over the past 20 years, Dr. Bernhard Hampl was a successful CEO in large American generics companies such as EON LABS Inc. and later Sandoz US, which after fusion of the two companies became America's second-largest manufacturer of generics. Dr. Hampl, who started his career at the German subsidiary of American Cyanamid /Lederle in Wolfratshausen near Munich, has been living in Connecticut/USA for the past 20 years and brings wide-ranging international experience to Formycon. Today, he advises companies from the field of pharmaceuticals and biotechnology as well as investment companies. For Formycon AG, which has now progressed into the advanced phases of preclinical development with its first projects and is striving for international cooperations - above all in the USA - the expertise provided by Dr. Hampl, who has a doctorate in the field of pharmaceutical chemistry, represents a very valuable addition to the competences of the Advisory Boards.
Dr. Carsten Brockmeyer, CEO of Formycon AG, said. "I'm very pleased that we were able to enlist Dr. Bernhard Hampl, a recognised expert who knows his way around the US pharmaceuticals market and who successfully built up and managed several pharmaceutical companies in the USA. His competence will be highly regarded in the Advisory Board."
This press release may contain future-oriented statements and information that are recognisable by formulations such as 'expect', 'want', 'anticipate', 'intend', 'plan', 'believe', 'strive', 'estimate', 'will be' or similar terms. Such forward-looking statements are based on our expectations today and on certain assumptions that may entail a range of risks and uncertainties. The results actually achieved by Formycon AG may deviate considerably from the declarations in the future-related statements. Formycon AG will not undertake any commitment to update these future-oriented statements or to correct them in the event that the situation develops differently than expected.
Formycon AG is a leading independent developer of biosimilars for global marketing and has taken on a clear pioneering role in this field. The team of the present Formycon AG has amassed many years of experience in the development of complex molecules. As early as 2008 and 2011, two protein-based product portfolios were licensed out to large pharmaceutical companies.
As a result of its particular expertise, Formycon AG is in a position to develop high-quality biosimilars that fulfil the strict requirements of the marketing authorisation authorities in the highly regulated countries and regions such as Europe and the USA. Formycon currently has two products under development, with the first biosimilar candidate already having been licensed out to Santo Holding GmbH. Further product developments are in the planning phase. The aim is to be the first company in the world to present clinical data for each respective product candidate and thus to license the products out to large pharmaceutical and generics companies for further development. Alternatively, Formycon offers to bring the biosimilars to marketing authorisation on behalf of the licensee and take over production.